26. Grenga I, Donahue RN, Gargulak ML, Lepone LM, Roselli M, Bilusic M, Schlom J: Anti -PD-L1/TGFbetaR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune -mediated recognition and lysis . Urol Oncol 2018, 36(3):93 e91-93 e11. 27. Jochems C, Tritsch SR, Pellom ST, Su Z, Soon-Shiong P, Wong HC, Gulley JL, Schlom J: Analyses of functions of an anti- PD-L1/TGFbetaR2 bispecific fusion protein (M7824) . Oncotarget 2017, 8(43):75217-75231. 28. Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J, Gameiro SR: M7824, a novel bifunctional anti -PD-L1/TGFbeta Trap fusion protein, promotes anti- tumor efficacy as monotherapy and in combination with vaccine . Oncoimmunology 2018, 7(5):e1426519. 29. Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernandez VM et al : Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF- beta. Sci Transl Med 2018, 10(424). 30. Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, Makarev E, A VA, Wysocki PT, Mehra R et al : Bifunctional immune checkpoint -targeted antibody - ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy . Nat Commun 2018, 9(1):741. 31. David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C: A novel bifunctional anti -PD-L1/TGF -beta Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells . Oncoimmunology 2017, 6(10):e1349589. 32. Strauss J, Heery C, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marte JL, Donahue RN, Grenga I et al : Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in advanced solid tumors . Clin Cancer Res 2018.